Displaying drugs 14851 - 14875 of 14995 in total
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes. These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A.
Experimental
Matched Description: … containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and …
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
R048-8071
Experimental
4-Phenylbutylamine
Experimental
2,3-Difluorobenzyl Alcohol
Experimental
Phenethylamine
Experimental
Soneclosan
Experimental
3-Phenylpropylamine
Experimental
2,5-di-tert-butylhydroquinone
Experimental
(S)-4-Nitrostyrene oxide
Experimental
p-Cumylphenol
Experimental
5-PENTYL-2-PHENOXYPHENOL
Experimental
N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
Experimental
Displaying drugs 14851 - 14875 of 14995 in total